INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common neoplasm in theworld, and the third most common cause of cancer-related death. The burden of this devastating cancer is expected to increase further in coming years [1] .As most patients with HCC are diagnosed at an advanced stage with underlying liver dysfunction, the mortality rate of HCC is similar to the incidence rate. Early detection of HCC is therefore extremely important in improving the survival of patients [2] .
Approximately 70%-90% of patients with HCC have an established background of chronic liver disease and cirrhosis, with major risk factors for developing cirrhosis including chronic infection with hepatitis B virus (HBV),hepatitis C virus (HCV), alcoholic liverdisease, and nonalcoholic steatohepatitis(NASH). Patients with cirrhosis are thus usually included in surveillance plans [3] .
AFP is the most widely tested biomarker in HCC. But the clinical value of AFP is challenged due to low sensitivity and specificity. AFP is not elevated in all patients with HCC. Some patients with cirrhosis and/or hepatic inflammation can have an elevated AFP, even withoutthe presence of a tumor [4] . Alternative serum biomarkers are being actively sought include prothrombin induced byvitamin K absence (PIVKA), glypican-3, and squamous cell carcinoma antigen-1; however, none of these have been adequately investigated to be recommended as a screening test [5] .
Golgi protein 73 (GP73) also named Golgi phosphorprotein 2 (GOLPH2), is a type II Golgi localized integral membrane protein that is normallyexpressed in epithelial cells of many human tissues. GP73 was first identified in a genetic screen for proteins with differential expression in adult giant-cell hepatitis (GCH) [6] . It is consistently present in biliary epithelial cells in normal livers, and hepatocytes show little or no signal. However, GP73 expression is upregulated in hepatocytes, and in serum samples from patients with acute & chronic hepatitis and liver cirrhosis regardless the etiology [7] . The aim of the present work was to study the diagnostic role of serum Golgi protein 73level as a marker for HCC in comparison with serum Alpha-fetoprotein. 
PATIENTS AND METHODS

Statistical Analysis:
The data were collected, tabulated, and analyzed by SPSS (statistical package for social science) version 17.0 on IBM compatible computer. Significance of results: Non-significant difference if P >0.05, Significant difference if P < 0.05 and highly significant difference if P < 0.01.
RESULTS
Demographics of the studied groups
There was no significant difference between the three studied groups as regards age and sex. Chronic HCV was the commonest etiology of cirrhosis in GI (85.4%) and GII patients (80.0%) while chronic HBV was far less common etiology.
There was non-significant difference between HCC group and cirrhotic group as regards the Child classification.
Triphasic CT revealed evidence of cirrhosis in all GI & GII patients as well as imaging evidence consistent with HCC in in all GI patients (Table  1 ).
There was highly significant increase in mean values of serum AFP & GP73 in HCC group in comparison with other groups and in cirrhotic group in comparison with control group (Table 2) .
There was no significant difference in mean values of AFP as regard tumor size in the HCC group, While there was statistical significant increase in the mean values of Gp73 with increasing the tumor size (more than 5 cm) ( Table 3 and Figure 1 ). (Table 5) .
Receiver operating characteristic curve (ROC curve) of AFP and GP73 for diagnosis of HCC versus cirrhotic cases showed that the cutoff point was 55ng/ml for AFP and 847.5ng/l for GP73 (Figure 2 ).
At cut off point 55 ng/ml, AFP had sensitivity 81.3%, specificity 70.0%, and accuracy 77.9%, while for Gp73 at cut off point 847.5 ng/l, the sensitivity was 93.8%, specificity 90.0% and accuracy 92.6% in diagnosis of HCC. With combined use of AFP and Gp73: the sensitivity increased to 95.8% (Table 6) . Correlation between GP73 and tumor size r = + 0.45 P value = 0.001 Regarding the gender distribution, the present study showed that HCC is more prevalent in men than in women with 3.8 times higher in men, these results were in agreement with ElSerag [10] who reported that there was a striking male HCC predominance, with the highest male: female ratios (averaging between 2:1 and 4:1) in high HCC incidence areas. Male sex predominance of HCC may be attributed to sex hormones and sex-specific differences in exposure to risk factors. Men are more likely to be infected with HBV and HCV, consume alcohol, smoke cigarettes, and have increased iron stores. However, experiments show a 2 -8 fold increase in HCC development in male mice. These data support the hypothesis that androgens influence HCC progression rather than sex-specific exposure to risk factors [10] . Several studies conducted in Taiwan reported a positive association between increased circulating testosterone levels and HCC in HBV-infected men [12] .
In the present study, Chronic HCV was the commonest etiology of cirrhosis in HCC group found that chronic HBV infection is the major factor for the development of HCC in China.
As regards the relation between HCC and the severity of cirrhosis, the present study revealed that about two thirds of HCC patients (66.7%) were Child C cirrhosis, 22.9% of the patients were Child B and 10.4% were Child A liver cirrhosis). These results were in agreement with Amer et al. [8] who found that 54.65% of HCC patients were Child C cirrhosis and HCC occurred least frequently in patients with Child A liver cirrhosis (15.4%).
The present study revealed a higher level of AFP in both cirrhotic and HCC groups than the control group and it is significantly higher in HCC group when compared to cirrhotic and control groups. AFP levels in cirrhotic group ranged from 1 to 90ng/ml and in HCC group it was 1.9-2850ng/ml. In the current study the area under AUROC for AFP was 0.88 and at cut off point 55 ng/ml, the sensitivity of AFP was 81.3% and specificity was 70.0%. Trevisani et al. [30] reported that specificity of AFP varied from about 76% to 96% and increased with elevated cutoff value, also El Shafie et al. [20] found that AFP had a sensitivity of 77.4% and a specificity of 60% at a cut-off 28.51 ng/ml.
In our study the area under AUROC for GP73 was 0.98 with sensitivity 93.8% and specificity 90.0% at cut off point 847.5ng/l. Marrero and Lok [31] postulated that, GP73 is up-regulated in HCC and measurement of serum GP73 revealed a sensitivity and specificity of 69% and 75%, respectively. Also El Shafie et al. [20] postulated that GP73 had a sensitivity of 87% and a specificity of 95% at the optimal cut-off value of7.62 ng/ml. These results were disappointing with Gu et al. [32] who found that GP73 elevated in patients with liver disease but did not distinguish between HCC, cirrhosis, and chronic hepatitis. Riener et al.
[25] reported GP73 was surprisingly found to be decreased in HCC patients and doubt on the diagnostic utility of GP73 as a serum marker of HCC.
In our study we found that with combined use of AFP and GP73 there was significant increase in sensitivity of detection of HCC up to 95.8% than using either of them alone, these results were in agreement with Wang et al.
[33] and Mao et al.
[18] who reported that the combined measurement of GP73 and AFP can further increase the sensitivity for the detection of HCC, also Omran et al. [34] reported that by combining serum GP73 and AFP for the diagnosis of HCC, it was found that sensitivity rises to 93% and El Shafie et al. [20] reported that when GP73 used in combination with AFP, they lead to an enhanced sensitivity of detection of HCC up to 90.3%.
CONCLUSION
The sensitivity, accuracy and negative predictive value for diagnosis of HCC in cirrhotic patients increased to 95.8%, 88.2% and 87.5% respectively with combined assay of serum GP73 and serum AFP. Serum GP73 levels correlated positively with tumor size, portal vein thrombosis and lymph node involvement in cirrhotic patients with HCC.
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